Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1921 - Correlation between fatigue evaluated with a visual analog scale (VAS) and quality of life (QoL) in cancer patients treated with biosimilar epoetin alfa for chemotherapy-induced anemia (CIA): the CIROCO study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Jérôme Desrame

Citation

Annals of Oncology (2018) 29 (suppl_8): viii603-viii640. 10.1093/annonc/mdy300

Authors

J. Desrame1, J. Loup Mouysset2, T. Altwegg3, L. Zelek4, N. Baize5

Author affiliations

  • 1 Institut Privé De Cancérologie, Hôpital privé Jean Mermoz, 69373 - Lyon/FR
  • 2 Department Of Medical Oncology, Clinique Rambot Provençale, Aix-en-Provence/FR
  • 3 Oncology, Institut de Cancérologie de Bourgogne, Dijon/FR
  • 4 Oncology Department, Hôpital Avicenne, Bobigny/FR
  • 5 Oncology, Centre hospitalier Universitaire d'Angers, Angers/FR
More

Resources

Abstract 1921

Background

Anemia often occurs in cancer patients receiving chemotherapy. QoL can be affected by symptoms of anemia, fatigue being the most common. Evaluation of QoL with validated tools (eg EORTC QLQ C30) is time-consuming. Correlation between fatigue assessed with a VAS and QoL is unclear. Aim: To determine the correlation between fatigue assessed by a VAS and QoL in cancer patients treated with biosimilar epoetin alfa (Sandoz) for CIA.

Methods

CIROCO is a non-interventional, prospective, multicenter study of adult patients (Full Analysis Set [FAS] population, n = 538) with ≥2 cycles of chemotherapy planned after study inclusion, with CIA and receiving biosimilar epoetin alfa. Data were collected on day of inclusion (T0), and after 2–3 (follow-up; T1) and 4–6 chemotherapy cycles (end of follow-up; T2). Patients and physicians separately assessed fatigue using a VAS (range 0–10); patients assessed QoL with the EORTC QLQ C30 questionnaire.

Results

Data are reported for a subgroup of patients with solid tumors (FAS population, n = 434). Mean (SD) hemoglobin (Hb) at baseline was 9.7 (±0.8) g/dL. Mean (SD) increase in Hb was 1.2 (±1.4) g/dL between T0 and T1 and 0.4 (±1.5) g/dL between T1 and T2. In the safety population (n = 464), 151 (32.5%) had adverse events (AEs; n = 320), 64 patients (13.8%) had serious AEs (n = 144) and 14 patients (3%) experienced AEs considered related to study treatment (n = 25). In the FAS population, between T0 and T2, mean (SD) change in fatigue VAS score (patient-reported) was +5.2 (±92.6) % and mean (SD) change in QoL was 29.9 (±98.0) %. The Pearson correlation coefficient for fatigue VAS score and QoL was –0.4993 (p < 0.0001) at T0, –0.5726 (p < 0.0001) at T1, and –0.5681 (p < 0.0001) at T2. Using fatigue VAS, physician assessment of fatigue was consistent with patient perceptions at T0 (5.0±2.1 vs 5.3±2.2), T1 (4.3±2.2 vs 4.8±2.3) and T2 (4.2±2.3 vs 4.7±2.3).

Conclusions

Biosimilar epoetin alfa was effective in this study, with improvements observed in Hb and QoL. A correlation was observed between reduced fatigue assessed with a VAS and improved QoL.

Clinical trial identification

Legal entity responsible for the study

Sandoz SAS.

Funding

Sandoz SAS.

Editorial Acknowledgement

Tony Reardon, Spirit Medical Communications Ltd.

Disclosure

N. Baize: Steering Committee member: CIROCO study. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.